Hikma Pharmaceuticals PLC (LON:HIK)
London · Delayed Price · Currency is GBP · Price in GBX 1,636.00
+12.00 (0.74%)
Aug 21, 2026, 4:35 PM GMT
Hikma Pharmaceuticals Ratios and Metrics
Market cap in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,442 | 3,433 | 4,419 | 3,955 | 3,418 | 5,136 | |
Market Cap Growth | -14.19% | -22.33% | 11.74% | 15.72% | -33.45% | -11.50% |
Enterprise Value | 4,710 | 4,407 | 5,234 | 4,766 | 4,383 | 5,569 |
Last Close Price | 16.36 | 14.81 | 18.43 | 16.03 | 13.54 | 18.90 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.35 | 11.49 | 15.41 | 26.52 | 21.91 | 16.52 |
Forward PE | 9.35 | 8.95 | 10.90 | 10.80 | 9.65 | 14.20 |
PS Ratio | 1.34 | 1.38 | 1.77 | 1.75 | 1.64 | 2.72 |
PB Ratio | 1.80 | 1.77 | 2.38 | 2.28 | 1.92 | 2.82 |
P/TBV Ratio | 3.28 | 3.25 | 4.79 | 4.59 | 4.07 | 4.46 |
P/FCF Ratio | 19.19 | 19.33 | 13.87 | 11.48 | 10.51 | 14.11 |
P/OCF Ratio | 9.34 | 10.60 | 9.81 | 8.29 | 7.77 | 10.90 |
PEG Ratio | 1.32 | 1.24 | 1.66 | 1.55 | 2.10 | 1.49 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.83 | 1.77 | 2.10 | 2.11 | 2.10 | 2.95 |
EV/EBITDA Ratio | 7.02 | 7.04 | 8.26 | 7.62 | 7.88 | 10.50 |
EV/EBIT Ratio | 9.19 | 9.15 | 10.67 | 9.71 | 10.61 | 13.44 |
EV/FCF Ratio | 26.26 | 24.82 | 16.42 | 13.83 | 13.47 | 15.30 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.77 | 0.62 | 0.56 | 0.54 | 0.60 | 0.34 |
Debt / EBITDA Ratio | 2.20 | 1.88 | 1.63 | 1.46 | 1.88 | 1.16 |
Debt / FCF Ratio | 8.22 | 6.71 | 3.27 | 2.71 | 3.27 | 1.72 |
Net Debt / Equity Ratio | 0.66 | 0.52 | 0.47 | 0.44 | 0.46 | 0.16 |
Net Debt / EBITDA Ratio | 1.90 | 1.62 | 1.38 | 1.21 | 1.48 | 0.55 |
Net Debt / FCF Ratio | 7.01 | 5.70 | 2.74 | 2.19 | 2.53 | 0.80 |
Asset Turnover | 0.60 | 0.62 | 0.64 | 0.63 | 0.57 | 0.60 |
Inventory Turnover | 1.69 | 1.81 | 1.82 | 1.76 | 1.70 | 1.73 |
Quick Ratio | 1.02 | 0.91 | 0.60 | 0.82 | 1.05 | 1.31 |
Current Ratio | 1.98 | 1.82 | 1.14 | 1.57 | 1.86 | 2.06 |
Return on Equity (ROE) | 15.41% | 16.52% | 15.98% | 8.81% | 8.28% | 18.20% |
Return on Assets (ROA) | 7.47% | 7.50% | 7.82% | 8.54% | 7.04% | 8.24% |
Return on Invested Capital (ROIC) | 12.40% | 13.77% | 14.84% | 13.54% | 13.60% | 15.48% |
Return on Capital Employed (ROCE) | 15.30% | 15.40% | 19.50% | 18.70% | 14.70% | 16.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 8.48% | 8.70% | 6.49% | 3.77% | 4.57% | 6.05% |
FCF Yield | 5.21% | 5.17% | 7.21% | 8.71% | 9.52% | 7.09% |
Dividend Yield | 3.78% | 4.21% | 3.47% | 3.52% | 3.43% | 2.11% |
Payout Ratio | 47.55% | 46.02% | 48.75% | 72.10% | 66.49% | 28.50% |
Buyback Yield / Dilution | 0.92% | 0.36% | -0.51% | 1.13% | 3.47% | 2.10% |
Total Shareholder Return | 4.70% | 4.58% | 2.96% | 4.65% | 6.91% | 4.21% |